A Phase II Trial Of ZD 1839 [gefitinib] (IRESSA) (NSC 715055, IND 61187) In The Treatment Of Persistent Or Recurrent Endometrial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2013
At a glance
- Drugs Gefitinib (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Sep 2011 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
- 30 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.